Gilead licenses Manufacturing and Distribution of Generic Versions of Viread to India-Based Companies
The license agreements require that the generic manufacturers meet certain national and international regulatory standards and include a technology transfer to enable expeditious production of large volumes of high-quality generic versions of tenofovir. In addition, these agreements allow the manufacture of commercial quantities of both active pharmaceutical ingredient (API) and finished product. Gilead continues to pursue license agreements with additional Indian generic manufacturers and is currently in ongoing discussions with a number of Indian companies.
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.